Nearly half of the older patients with acute myeloid leukemia in the ASCERTAIN V trial took a simple handful of pills each day and watched cancer cells disappear—no monthly trips to the hospital for intravenous infusions required. The FDA approved this all-oral combination of decitabine-cedazuridine and venetoclax on May 13, marking a quiet revolution in how one of the most aggressive blood cancers is treated in those who need options most.
For decades, patients 75 and older with AML, or those too frail for intensive chemotherapy, faced a grueling standard treatment: monthly cycles that meant repeated hospital or office visits for injectable drugs mixed with oral pills taken at home. The physical toll was real—the logistical burden of coordinating care, the emotional weight of frequent medical appointments, the disruption to daily life. The international Phase I/Phase II trial, led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, Yale University, and MD Anderson Cancer Center, asked a straightforward question: could swallowing pills instead achieve the same results?
The answer lay in a pharmacological breakthrough. Scientists had developed an oral form of decitabine—a hypomethylating agent that restores activity to genes involved in cancer control—by pairing it with cedazuridine, a drug that prevents decitabine from being broken down during digestion. Combined with venetoclax, which disables a protein that leukemia cells overproduce to survive, this two-pill regimen offered a chance to test whether convenience could match efficacy.
Across 189 newly diagnosed AML patients enrolled at centers in the United States, Canada, and Spain, the results proved compelling. Nearly half—46.5 percent—achieved complete response, with cancer cells becoming undetectable. When researchers added patients who experienced complete response with incomplete hematologic recovery (meaning leukemia was gone but healthy blood cells hadn't fully bounced back), that figure climbed to 63 percent. The median overall survival reached 15.5 months, matching what doctors saw with traditional intravenous therapies.
"Having received approval, we anticipate that this oral AML regimen will become the standard of care for patients who are older or more frail," said Dr. Gail J. Roboz, the trial's lead author and director of the Clinical and Translational Leukemia Program at Weill Cornell. She added a hope that resonated through the study: "We hope these results point to a future for AML patients where the treatment journey is less disruptive and less burdensome without sacrificing outcomes."
The safety profile aligned with what oncologists already expect from AML therapies—the most common serious side effects included anemia, neutropenia (low infection-fighting white blood cells), and fever. Yet the researchers went further, offering physicians practical guidance on fine-tuning treatment schedules: careful monitoring of leukemia cells, then strategic pauses in venetoclax to allow the body to rebuild healthy blood counts.
For patients already managing the physical and emotional weight of an aggressive blood cancer diagnosis, the shift from monthly infusion cycles to a daily pill regimen represents more than mere convenience. It is recognition that outcomes and quality of life need not be traded off against each other. The study, published in the New England Journal of Medicine, offers older adults and frail patients something they rarely get: a treatment that works as well as the standard, but demands far less from their bodies and their lives.